Duane Barker and John Holliday
Blood Lymphocyte and Neutrophil Response of Cultured Rainbow Trout, Oncorhynchus mykiss, Administered Varying Dosages of an Oral Immunomodulator – ‘FinImmune™’
1 - 5
2009
3
1
International Journal of Biomedical and Biological Engineering
https://publications.waset.org/pdf/14606
https://publications.waset.org/vol/25
World Academy of Science, Engineering and Technology
In a 10week (May – August, 2008) Phase I trial, 840, 1 rainbow trout, Oncorhynchus mykiss, received a commercial oral immunomodulator, Fin Immune™, at four different dosages (0, 10, 20 and 30 mg g1) to evaluate immune response and growth. The overall objective of was to determine an optimal dosage of this product for rainbow trout that provides enhanced immunity with maximal growth and health. Biweekly blood samples were taken from 10 randomly selected fish in each tank (30 samples per treatment) to evaluate the duration of enhanced immunity conferred by FinImmune™. The immunological assessment included serum white blood cell (lymphocyte, neutrophil) densities and blood hematocrit (packed cell volume ). Of these three variables, only lymphocyte density increased significantly among trout fed Fin Immune™ at 20 and 30 mg g1 which peaked at week 6. At week 7, all trout were switched to regular feed (lacking FinImmune™) and by week 10, lymphocyte levels decreased among all levels but were still greater than at week 0. There was growth impairment at the highest dose of FinImmune™ tested (30 mg g1) which can be associated with a physiological compensatory mechanism due to a dosespecific threshold level. Thus, our main objective of this Phase I study was achieved, the 20 mg g1 dose of FinImmune™ should be the most efficacious (of those we tested) to use for a Phase II disease challenge trial.
Open Science Index 25, 2009